IP Library Granted Patent US 7,901,714
Granted Patent B2
US 7,901,714 · App. 11/649,584 · Granted Mar 8, 2011

Treatment modalities for autoimmune diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,901,714
App. No.
11/649,584
Granted
Mar 8, 2011
Kind
B2
Abstract

Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.

Claims (8)

1. A composition for treating an autoimmune disease, said composition comprising therapeutically effective amounts of (a) a compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone (b) at least one mineral, and (c) at least one vitamin, wherein said composition is in tablet or capsule form for administration to a subject suffering from an autoimmune disease.

2. The composition of claim 1 , wherein the at least one mineral is selected from the group consisting of calcium, selenium, zinc, copper, iron, chromium, magnesium, manganese, vanadium, molybdenum, and boron.

3. The composition of claim 1 , wherein the at least one mineral is selected from the group consisting of selenium and zinc.

4. The composition of claim 1 , wherein the at least one vitamin is selected from the group consisting of Vitamin A, Vitamin B, Vitamin C, Vitamin D, Vitamin E, Vitamin K, biotin, folate, pantothenic acid, para-aminobenzoic acid, and betaine.

5. The composition of claim 1 , wherein the at least one vitamin is Vitamin D.

6. The composition of claim 1 , wherein the composition comprises about 0.5 to 10,000 mg of the compound.

7. The composition of claim 1 , wherein the composition comprises about 50 to 7,500 mg of the compound.

8. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2007
From: TRIPP, MATTHEW L.; BLAND, JEFFREY S.; LERMAN, ROBERT; HALL, AMY J.; KONDA, VEERA; DESAI, ANU
To: METAPROTEOMICS, LLC
Reel/Frame 019079/0075 →